Although a recent Japanese study of patients with MBC suggested that BRCA1/2 profiling combined with olaparib treatment provided a minimal incremental benefit versus standard chemotherapy alone [30], other studies have demonstrated cost-effectiveness of routine/mainstream genetic testing for all patients diagnosed with breast cancer to guide subsequent personalized therapy [31, 32]. This evidence concerns the gene BRCA1 and breast cancer.